Next-generation fusion company SHINE Technologies and WARF Therapeutics, a drug discovery programme from the Wisconsin Alumni Research Foundation (WARF), announced on Thursday promising pre-clinical research results from collaborative efforts with the Advanced Radiotheranostics Lab at the University of Wisconsin-Madison.
The studies showed that WT-7695 and ART-101, treatments that uses Ilumira, SHINE's non-carrier added lutetium-177 (Lu-177) chloride, have the potential to increase life span and be more effective in treating kidney and prostate cancer, respectively.
Partnering with UW-Madison and Morgridge Institute for Research Principal Investigators, WARF Therapeutics creates a translational research path that draws on research and an industry-focused approach to improve value propositions of drug candidates.
WARF Therapeutics has invested to accelerate the development of theranostic radiopharmaceutical programs at UW-Madison, like WT-7695 and ART-101, while SHINE Technologies provides the lutetium-177 integral to this innovative cancer treatment approach.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study